International Stem Cell Corp., a California-based biotech
company developing novel stem cell-based therapies and biomedical products,
this morning said it will make an oral presentation on the comprehensive
results of its preclinical development of human parthenogenetic neural stem
cells (hPNSCs) for the treatment of Parkinson’s Disease at the upcoming
Neuroscience 2015 in Chicago.
The session, entitled, “Therapeutics of Parkinson’s Disease:
Preclinical Studies,” will take place October 20 from 8 a.m.-10:15 a.m. ET.
“The comprehensive data collected from our extensive GLP
studies serve as proof of safety and efficacy for our planned clinical trial
for the treatment of Parkinson’s Disease in Australia. We look forward to
providing an update on the status of our regulatory submission to the
Australian government in the near future,” Russell A. Kern, Ph.D. chief
scientific officer of ISCO, stated in the news release.
ISCO’s Parkinson’s disease program uses human
parthenogenetic neural stem cells (hPNSC), which are a novel therapeutic
cellular product derived from ISCO’s proprietary human pluripotent stem cells.
hPNSC are self-renewing multipotent cells that are precursors for the major
cells of the central nervous system. The ability of hPNSC to differentiate into
dopaminergic neurons and express neurotrophic factors to protect the
nigrostriatal system offers a new opportunity for the treatment of Parkinson’s
disease.
ISCO also produces and markets specialized cells and growth
media for therapeutic research worldwide through its subsidiary Lifeline Cell
Technology (www.lifelinecelltech.com), and stem cell-based skin care products
through its subsidiary Lifeline Skin Care (www.lifelineskincare.com).
For more information visit www.internationalstemcell.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
